|
LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. Clinical research trials and LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.. LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. clinical trial. Human subjects often get the best healthcare possible for their LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.  LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
For Condition: Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Non-Insulin-Dependent,Diabetic Neuropathies
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients must have type I or type II Diabetes Mellitus. - Have clinically diagnosed positive sensory symptoms such as numbness, lancinating pain, burning pain, aching pain, allodynia and prickling sensation that have been present not greater than 5 years but stable for 6 months. - Has a HbA1C less than or equal to 12%. Patients with HbA1C greater than 9% must be insulin therapy. - Must be 18 years or older. - Be able to visit the doctor's office approximately 3 times over a maximum of a 6-week period to determine if you can continue in the study. Exclusion Criteria: - History of significant liver problems. - Have poor kidney function. - Drink an excess of alcohol or abuse drugs. - Have recently participated or currently participating in a Medical study in which you receive an experimental drug. - Are a woman and are pregnant or breastfeeding, intend to become pregnant within the next 2 years or a woman not using effective birth control.
Total Enrollment:
Location and Contact Information:
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Amersfoort, ,
Netherlands
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Baltimore, Maryland,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
New York City, New York,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Norwalk, Connecticut,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Klaipeda, ,
Lithuania
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Halifax, Nova Scotia,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Columbia, South Carolina,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Poole, Dorset,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Shrewsbury, Shropshire,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Zagreb, ,
Croatia
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Minneapolis, Minnesota,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
San Antonio, Texas,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Norwalk, Connecticut,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Laval, Quebec,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Boston, Massachusetts,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Vancouver, British Columbia,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Columbia, Missouri,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Salford, Manchester,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Kaunas, ,
Lithuania
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Clearwater, Florida,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Vilnus, ,
Lithuania
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Columbia, Missouri,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Idaho Falls, Idaho,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Manchester, ,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Toronto, Ontario,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
North Chicago, Illinois,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Sheffield, South Yorkshire,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Mumbai, Maharashtra,
India
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Oulu, ,
Finland
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Long Beach, California,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Plantation, Florida,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Gopalapuram, Chennai,
India
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Jyvaskyla, ,
Finland
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Hyderabad, ,
India
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Winnipeg, Manitoba,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Charlottetown, Prince Edward Island,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Helsinki, ,
Finland
Additional Information:
Study ID Numbers: 6204;
Study Start Date: July 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00044408
Other Diabetes Mellitus, Non-Insulin-Dependent Studies:
1. The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)
2. NNC 90-1170 Mechanism of Action: A double-blind, randomized, single-center, placebo-controlled, crossover study to examine beta-cell responsiveness to graded glucose infusion in subjects with type 2 diabetes
3. Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
4. Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes
5. Education and Group Support for Diabetic Hispanics
Related Studies:
Other Diabetes Mellitus, Non-Insulin-Dependent Clinical Trials
Other South Yorkshire Clinical Trials
Other Sheffield Clinical Trials
LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
|
|
|
|
|
|
|
|
